Abbott Laboratories announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms. The data shows the Aveir device met its pre-specified primary endpoints and suggest that the Aveir system, once approved, could offer new benefits for patients who require the use of a pacemaker to treat slow heart rhythms. The findings were presented in a late-breaking session at the annual Scientific Sessions of the Asia Pacific Heart Rhythm Society and simultaneously published in the Journal of the American College of Cardiology: Clinical Electrophysiology. The data from the study has also been submitted to the U.S. Food & Drug Administration as the Aveir leadless pacemaker is evaluated for U.S. approval. People who experience slower-than-normal heart rates may receive a pacemaker to restore a more normal heart rate. Yet unlike traditional pacemakers, leadless pacemakers do not require an incision in the chest to implant the device or insulated wires ? known as cardiac leads ? to deliver energy to the heart. Instead, leadless pacemakers are implanted directly into the heart's right ventricle via a minimally invasive procedure, requiring no cardiac leads to deliver therapy. Under the Leadless II trial design, primary safety and efficacy endpoints were analyzed in the 200 patients enrolled in 43 centers in the U.S., Canada and Europe. Patients were followed for six weeks. Results of the study showed: Successful implant of the Aveir leadless pacemaker in 98% of patients. At six weeks post-implant, 96% of patients met the safety endpoint of no serious adverse device effects and 95.9% achieved the efficacy endpoint of acceptable therapy delivered to the patient (known as therapeutic pacing threshold and sensing amplitude). Additionally, physicians were able to accurately position the device either the first time or with a single repositioning in 96% of clinical cases. The Leadless II IDE study is a prospective, non-randomized, multicenter study designed to evaluate the clinical safety and efficacy of the Aveir leadless pacemaker in patients who were indicated for a VVI(R) ? or ventricular demand pacing ? pacemaker, which stimulates the heart only if the heart rate falls below a set level. For the primary endpoint analyses, all patients were followed for six weeks post-implant to evaluate potentially serious adverse device effects. During this time, efficacy was measured as acceptable pacing capture threshold and sensing amplitude.